Meeting
2017 ASCO Annual Meeting
Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.
Authors
Amod Sarnaik
Moffitt Cancer Center, Tampa, FL
Amod Sarnaik , Harriet M. Kluger , Jason Alan Chesney , Jyothi Sethuraman , Anandharamen Veerapathran , Michelle Simpson-Abelson , Michael T. Lotze , Bente Larsen , Steven A. Fischkoff , Sam Suzuki , Lei Wang , Mariam Mirgoli , Maria Fardis , Brendan D. Curti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Cellular Immunotherapy
Clinical Trial Registration Number
NCT02360579
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3045)
DOI
10.1200/JCO.2017.35.15_suppl.3045
Abstract #
3045
Poster Bd #
140
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.
First Author: Amod Sarnaik
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.
First Author: Amod Sarnaik
Poster
2016 ASCO Annual Meeting
Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.
First Author: MarnixMarnix Heimen Geukes Foppen
Poster
2019 ASCO Annual Meeting
Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM).
First Author: Rodabe Navroze Amaria